

Global Acute Myeloid Leukaemia Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GD1FD3D65684EN.html>

Date: September 2023

Pages: 101

Price: US\$ 3,480.00 (Single User License)

ID: GD1FD3D65684EN

Abstracts

According to our (Global Info Research) latest study, the global Acute Myeloid Leukaemia Therapeutics market size was valued at USD 3601.3 million in 2022 and is forecast to a readjusted size of USD 7125.8 million by 2029 with a CAGR of 10.2% during review period.

The Global Info Research report includes an overview of the development of the Acute Myeloid Leukaemia Therapeutics industry chain, the market status of Specialty Clinics (Chemotherapy, Targeted Therapy), Hospital (Chemotherapy, Targeted Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Acute Myeloid Leukaemia Therapeutics.

Regionally, the report analyzes the Acute Myeloid Leukaemia Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Acute Myeloid Leukaemia Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Acute Myeloid Leukaemia Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Acute Myeloid Leukaemia Therapeutics industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Chemotherapy, Targeted Therapy).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Acute Myeloid Leukaemia Therapeutics market.

Regional Analysis: The report involves examining the Acute Myeloid Leukaemia Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Acute Myeloid Leukaemia Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Acute Myeloid Leukaemia Therapeutics:

Company Analysis: Report covers individual Acute Myeloid Leukaemia Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Acute Myeloid Leukaemia Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Specialty Clinics, Hospital).

Technology Analysis: Report covers specific technologies relevant to Acute Myeloid Leukaemia Therapeutics. It assesses the current state, advancements, and potential future developments in Acute Myeloid Leukaemia Therapeutics areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Acute Myeloid Leukaemia Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Acute Myeloid Leukaemia Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hypomethylating Agents

Others

Market segment by Application

Specialty Clinics

Hospital

Others

Market segment by players, this report covers

Pfizer Inc.

Novartis AG

Celgene Corporation

Astellas Pharma Inc.

Daiichi Sankyo Company, Limited

Jazz Pharmaceuticals

Boehringer Ingelheim International GmbH

Johnson & Johnson

Gilead Sciences, Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Sunesis Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Acute Myeloid Leukaemia Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Acute Myeloid Leukaemia Therapeutics, with revenue, gross margin and global market share of Acute Myeloid Leukaemia Therapeutics from 2018 to 2023.

Chapter 3, the Acute Myeloid Leukaemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Acute Myeloid Leukaemia Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukaemia Therapeutics.

Chapter 13, to describe Acute Myeloid Leukaemia Therapeutics research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Acute Myeloid Leukaemia Therapeutics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Acute Myeloid Leukaemia Therapeutics by Type
 - 1.3.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type in 2022
 - 1.3.3 Chemotherapy
 - 1.3.4 Targeted Therapy
 - 1.3.5 Immunotherapy
 - 1.3.6 Hypomethylating Agents
 - 1.3.7 Others
- 1.4 Global Acute Myeloid Leukaemia Therapeutics Market by Application
 - 1.4.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Specialty Clinics
 - 1.4.3 Hospital
 - 1.4.4 Others
- 1.5 Global Acute Myeloid Leukaemia Therapeutics Market Size & Forecast
- 1.6 Global Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Region
 - 1.6.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region, (2018-2029)
 - 1.6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.5 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.6 South America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.7 Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Pfizer Inc.

2.1.1 Pfizer Inc. Details

2.1.2 Pfizer Inc. Major Business

2.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Pfizer Inc. Recent Developments and Future Plans

2.2 Novartis AG

2.2.1 Novartis AG Details

2.2.2 Novartis AG Major Business

2.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Novartis AG Recent Developments and Future Plans

2.3 Celgene Corporation

2.3.1 Celgene Corporation Details

2.3.2 Celgene Corporation Major Business

2.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Celgene Corporation Recent Developments and Future Plans

2.4 Astellas Pharma Inc.

2.4.1 Astellas Pharma Inc. Details

2.4.2 Astellas Pharma Inc. Major Business

2.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Astellas Pharma Inc. Recent Developments and Future Plans

2.5 Daiichi Sankyo Company, Limited

2.5.1 Daiichi Sankyo Company, Limited Details

2.5.2 Daiichi Sankyo Company, Limited Major Business

2.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

- 2.5.5 Daiichi Sankyo Company, Limited Recent Developments and Future Plans
- 2.6 Jazz Pharmaceuticals
 - 2.6.1 Jazz Pharmaceuticals Details
 - 2.6.2 Jazz Pharmaceuticals Major Business
 - 2.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Solutions
 - 2.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Jazz Pharmaceuticals Recent Developments and Future Plans
- 2.7 Boehringer Ingelheim International GmbH
 - 2.7.1 Boehringer Ingelheim International GmbH Details
 - 2.7.2 Boehringer Ingelheim International GmbH Major Business
 - 2.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Solutions
 - 2.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
- 2.8 Johnson & Johnson
 - 2.8.1 Johnson & Johnson Details
 - 2.8.2 Johnson & Johnson Major Business
 - 2.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Solutions
 - 2.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 Johnson & Johnson Recent Developments and Future Plans
- 2.9 Gilead Sciences, Inc.
 - 2.9.1 Gilead Sciences, Inc. Details
 - 2.9.2 Gilead Sciences, Inc. Major Business
 - 2.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
 - 2.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Gilead Sciences, Inc. Recent Developments and Future Plans
- 2.10 Amgen Inc.
 - 2.10.1 Amgen Inc. Details
 - 2.10.2 Amgen Inc. Major Business
 - 2.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
 - 2.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin

and Market Share (2018-2023)

2.10.5 Amgen Inc. Recent Developments and Future Plans

2.11 Takeda Pharmaceutical Company Limited

2.11.1 Takeda Pharmaceutical Company Limited Details

2.11.2 Takeda Pharmaceutical Company Limited Major Business

2.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia

Therapeutics Product and Solutions

2.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia

Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans

2.12 Sunesis Pharmaceuticals, Inc.

2.12.1 Sunesis Pharmaceuticals, Inc. Details

2.12.2 Sunesis Pharmaceuticals, Inc. Major Business

2.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments and Future Plans

2.13 Agios Pharmaceuticals, Inc.

2.13.1 Agios Pharmaceuticals, Inc. Details

2.13.2 Agios Pharmaceuticals, Inc. Major Business

2.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

2.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.13.5 Agios Pharmaceuticals, Inc. Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Acute Myeloid Leukaemia Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Acute Myeloid Leukaemia Therapeutics by Company Revenue

3.2.2 Top 3 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2022

3.2.3 Top 6 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2022

3.3 Acute Myeloid Leukaemia Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Acute Myeloid Leukaemia Therapeutics Market: Region Footprint

3.3.2 Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint

3.3.3 Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country

6.3.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

6.3.3 Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)

7.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country

7.3.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)

7.3.2 Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region

8.3.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country

9.3.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country

10.3.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Acute Myeloid Leukaemia Therapeutics Market Drivers

11.2 Acute Myeloid Leukaemia Therapeutics Market Restraints

11.3 Acute Myeloid Leukaemia Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Acute Myeloid Leukaemia Therapeutics Industry Chain
- 12.2 Acute Myeloid Leukaemia Therapeutics Upstream Analysis
- 12.3 Acute Myeloid Leukaemia Therapeutics Midstream Analysis
- 12.4 Acute Myeloid Leukaemia Therapeutics Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Pfizer Inc. Company Information, Head Office, and Major Competitors

Table 6. Pfizer Inc. Major Business

Table 7. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 8. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Pfizer Inc. Recent Developments and Future Plans

Table 10. Novartis AG Company Information, Head Office, and Major Competitors

Table 11. Novartis AG Major Business

Table 12. Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 13. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Novartis AG Recent Developments and Future Plans

Table 15. Celgene Corporation Company Information, Head Office, and Major Competitors

Table 16. Celgene Corporation Major Business

Table 17. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 18. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Celgene Corporation Recent Developments and Future Plans

Table 20. Astellas Pharma Inc. Company Information, Head Office, and Major Competitors

Table 21. Astellas Pharma Inc. Major Business

Table 22. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 23. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

- Table 24. Astellas Pharma Inc. Recent Developments and Future Plans
- Table 25. Daiichi Sankyo Company, Limited Company Information, Head Office, and Major Competitors
- Table 26. Daiichi Sankyo Company, Limited Major Business
- Table 27. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions
- Table 28. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Daiichi Sankyo Company, Limited Recent Developments and Future Plans
- Table 30. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 31. Jazz Pharmaceuticals Major Business
- Table 32. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Solutions
- Table 33. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 34. Jazz Pharmaceuticals Recent Developments and Future Plans
- Table 35. Boehringer Ingelheim International GmbH Company Information, Head Office, and Major Competitors
- Table 36. Boehringer Ingelheim International GmbH Major Business
- Table 37. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Solutions
- Table 38. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 39. Boehringer Ingelheim International GmbH Recent Developments and Future Plans
- Table 40. Johnson & Johnson Company Information, Head Office, and Major Competitors
- Table 41. Johnson & Johnson Major Business
- Table 42. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Solutions
- Table 43. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 44. Johnson & Johnson Recent Developments and Future Plans
- Table 45. Gilead Sciences, Inc. Company Information, Head Office, and Major Competitors
- Table 46. Gilead Sciences, Inc. Major Business
- Table 47. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 48. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 49. Gilead Sciences, Inc. Recent Developments and Future Plans

Table 50. Amgen Inc. Company Information, Head Office, and Major Competitors

Table 51. Amgen Inc. Major Business

Table 52. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 53. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 54. Amgen Inc. Recent Developments and Future Plans

Table 55. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors

Table 56. Takeda Pharmaceutical Company Limited Major Business

Table 57. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 58. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 59. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans

Table 60. Sunesis Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors

Table 61. Sunesis Pharmaceuticals, Inc. Major Business

Table 62. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 63. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 64. Sunesis Pharmaceuticals, Inc. Recent Developments and Future Plans

Table 65. Agios Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors

Table 66. Agios Pharmaceuticals, Inc. Major Business

Table 67. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions

Table 68. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 69. Agios Pharmaceuticals, Inc. Recent Developments and Future Plans

Table 70. Global Acute Myeloid Leukaemia Therapeutics Revenue (USD Million) by Players (2018-2023)

Table 71. Global Acute Myeloid Leukaemia Therapeutics Revenue Share by Players (2018-2023)

Table 72. Breakdown of Acute Myeloid Leukaemia Therapeutics by Company Type

(Tier 1, Tier 2, and Tier 3)

Table 73. Market Position of Players in Acute Myeloid Leukaemia Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 74. Head Office of Key Acute Myeloid Leukaemia Therapeutics Players

Table 75. Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint

Table 76. Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint

Table 77. Acute Myeloid Leukaemia Therapeutics New Market Entrants and Barriers to Market Entry

Table 78. Acute Myeloid Leukaemia Therapeutics Mergers, Acquisition, Agreements, and Collaborations

Table 79. Global Acute Myeloid Leukaemia Therapeutics Consumption Value (USD Million) by Type (2018-2023)

Table 80. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Share by Type (2018-2023)

Table 81. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Type (2024-2029)

Table 82. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2023)

Table 83. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 84. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 85. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 86. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 87. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 88. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 89. North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 90. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 91. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 92. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by

Application (2018-2023) & (USD Million)

Table 93. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 94. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 95. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 96. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 97. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 98. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 99. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 100. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 101. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 102. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 103. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 104. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 105. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 106. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 107. South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 108. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 109. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 110. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 111. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 112. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 113. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 114. Acute Myeloid Leukaemia Therapeutics Raw Material

Table 115. Key Suppliers of Acute Myeloid Leukaemia Therapeutics Raw Materials

List Of Figures

LIST OF FIGURES

- Figure 1. Acute Myeloid Leukaemia Therapeutics Picture
- Figure 2. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type in 2022
- Figure 4. Chemotherapy
- Figure 5. Targeted Therapy
- Figure 6. Immunotherapy
- Figure 7. Hypomethylating Agents
- Figure 8. Others
- Figure 9. Global Acute Myeloid Leukaemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 10. Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application in 2022
- Figure 11. Specialty Clinics Picture
- Figure 12. Hospital Picture
- Figure 13. Others Picture
- Figure 14. Global Acute Myeloid Leukaemia Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 15. Global Acute Myeloid Leukaemia Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 16. Global Market Acute Myeloid Leukaemia Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
- Figure 17. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Region (2018-2029)
- Figure 18. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Region in 2022
- Figure 19. North America Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 20. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 21. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 22. South America Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Global Acute Myeloid Leukaemia Therapeutics Revenue Share by Players in 2022

Figure 25. Acute Myeloid Leukaemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 26. Global Top 3 Players Acute Myeloid Leukaemia Therapeutics Market Share in 2022

Figure 27. Global Top 6 Players Acute Myeloid Leukaemia Therapeutics Market Share in 2022

Figure 28. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Share by Type (2018-2023)

Figure 29. Global Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Type (2024-2029)

Figure 30. Global Acute Myeloid Leukaemia Therapeutics Consumption Value Share by Application (2018-2023)

Figure 31. Global Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Application (2024-2029)

Figure 32. North America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 33. North America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 34. North America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 35. United States Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 36. Canada Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 37. Mexico Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 38. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 39. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 40. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 41. Germany Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 42. France Acute Myeloid Leukaemia Therapeutics Consumption Value

(2018-2029) & (USD Million)

Figure 43. United Kingdom Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 44. Russia Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 45. Italy Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 46. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 47. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 48. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 49. China Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 50. Japan Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 51. South Korea Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 52. India Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. Southeast Asia Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 54. Australia Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 55. South America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 56. South America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 57. South America Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 58. Brazil Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 59. Argentina Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 60. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 61. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 62. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 63. Turkey Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 64. Saudi Arabia Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 65. UAE Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 66. Acute Myeloid Leukaemia Therapeutics Market Drivers

Figure 67. Acute Myeloid Leukaemia Therapeutics Market Restraints

Figure 68. Acute Myeloid Leukaemia Therapeutics Market Trends

Figure 69. Porters Five Forces Analysis

Figure 70. Manufacturing Cost Structure Analysis of Acute Myeloid Leukaemia Therapeutics in 2022

Figure 71. Manufacturing Process Analysis of Acute Myeloid Leukaemia Therapeutics

Figure 72. Acute Myeloid Leukaemia Therapeutics Industrial Chain

Figure 73. Methodology

Figure 74. Research Process and Data Source

I would like to order

Product name: Global Acute Myeloid Leukaemia Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GD1FD3D65684EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD1FD3D65684EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

